Rare diseases Marathon sells Duchenne drug to PTC PTC says it will make changes to the price after abandoned launch last month.
News Outrage at Marathon's 'new drug' price, calls for PhRMA to a... Marathon under fire after US price hike.
News Sarepta files controversial Duchenne drug in EU US biotech seeks conditional approval for eteplirsen in EU.
News PTC's muscular dystrophy drug can stay on EU market - regula... But PTC must conduct further trial to confirm Translarna's benefits.
News FDA's Duchenne drug approval greeted with joy, but remains c... FDA will require efficacy evidence.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
